FDA Accepts Supplement Application for STELARA by Janssen Biotech
The FDA has accepted a supplemental application for STELARA (ustekinumab) from Janssen Biotech.
Asset / Drug
Drug and asset intelligence for Janssen with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.